Efficacy and safety of dual add‐on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52‐week, randomized, active‐controlled trial

AIMS: To evaluate the efficacy and safety of dapagliflozin (DAPA) + saxagliptin (SAXA) compared with glimepiride (GLIM) in patients with type 2 diabetes who were inadequately controlled [glycated haemoglobin (HbA1c) 7.5–10.5% (58–91 mmol/mol)] on metformin monotherapy. MATERIALS AND METHODS: This 52...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Diabetes Obes Metab
Huvudupphovsmän: Frias, Juan P., Gonzalez‐Galvez, Guillermo, Johnsson, Eva, Maaske, Jill, Testa, Marcia A., Simonson, Donald C., Dronamraju, Nalina, Garcia‐Sanchez, Ricardo, Peters, Anne L.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Blackwell Publishing Ltd 2020
Ämnen:
Original Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7317565/
https://ncbi.nlm.nih.gov/pubmed/32052516
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13997
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk